How many clinical trials are studying GV20-0251?

3 recruiting trials in our tracked data involve GV20-0251.

What conditions is GV20-0251 being studied for?

In our tracked recruiting trials, GV20-0251 is being studied in trials for Melanoma, Endometrial Carcinoma (EC), HCC - Hepatocellular Carcinoma.

Recruiting trials

Conditions studied

US states with sites

Countries

Phase 1 3 Phase 2 2

Condition	Trials
Melanoma · GV20-0251 for Melanoma	3
Endometrial Carcinoma (EC)	2
HCC - Hepatocellular Carcinoma	2
Lung cancer	2
Non-Small Cell Lung Cancer	2
Squamous Head and Neck Carcinoma	2
pMMR/MSS Adenocarcinoma of the Colon or Rectum	2
Adult Refractory Cancer	1
Cholangiocarcinoma	1
Colorectal cancer	1
Cutaneous Melanoma	1
Endometrial Cancer	1
HNSCC	1
NSCLC (Non-small Cell Lung Cancer)	1
Pancreatic Ductal Adenocarcinoma	1

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
NCT07106827 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Study of GV20-0251 in Participants With Solid Tumor Malignancies
NCT07070518 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations